Objectives: To develop and verify a standardized protocol for HER2 immunohistochemical assays on invasive ductal carcinoma of the breast in Thailand. Material and Method: A two-phase study approach was employed. In the Phase One, after verifying the proposed protocol that adopted the HercepTest procedure using readily available primary antibodies, CB11 and A0485, Lab 1 performed the HER2 immunohistochemical staining for 137 cases of invasive ductal carci-noma twice with two types of the antibody. Nine pathologists from 8 centers independently examined and scored all the 2x137 stained slides that were blinded for antibody type. Interobserver reliability was calcu-lated using pair-wise kappa. Following discussion of the results, the Phase Two...
The tests that are currently available for the measurement of overexpression of the human epidermal ...
Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4 formalin-fixe...
The HercepTest was approved 20+ years ago as the companion diagnostic test for trastuzumab in human ...
This study investigated the degree of interlaboratory agreement when HER-2/neu was evaluated by immu...
Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4formalin-fixed...
ABSTRACT Introduction: Advances in the field of molecular biology have provided the differentiation...
AIMS: HER2 protein is over-expressed in 15-30% of breast carcinomas. Immunohistochemistry (IHC) is a...
Abstract. The HER2 gene is amplified and overexpressed in 25–30 % of breast carcinomas. Assessment o...
Breast cancer accounts for approximately one quarter of all cancers in females. HER2 gene amplificat...
OBJECTIVE: To determine the frequency of the immunohistochemical profiles of a series of high-grade ...
To retrospectively evaluate the HER2 status of 1 501 invasive breast cancer (IBC) by immunohistochem...
Objective: The aim of this study was to determine the rate of Her-2 gene amplification in breast can...
INTRODUCTION: Overexpression of the human epidermal growth factor receptor 2 (HER2) as a result of H...
Breast cancer accounts for approximately one quarter of all cancers in females. HER2 gene amplificat...
Purpose: Human epidermal growth factor receptor–2 (HER2) status can be tested with immunohistochemis...
The tests that are currently available for the measurement of overexpression of the human epidermal ...
Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4 formalin-fixe...
The HercepTest was approved 20+ years ago as the companion diagnostic test for trastuzumab in human ...
This study investigated the degree of interlaboratory agreement when HER-2/neu was evaluated by immu...
Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4formalin-fixed...
ABSTRACT Introduction: Advances in the field of molecular biology have provided the differentiation...
AIMS: HER2 protein is over-expressed in 15-30% of breast carcinomas. Immunohistochemistry (IHC) is a...
Abstract. The HER2 gene is amplified and overexpressed in 25–30 % of breast carcinomas. Assessment o...
Breast cancer accounts for approximately one quarter of all cancers in females. HER2 gene amplificat...
OBJECTIVE: To determine the frequency of the immunohistochemical profiles of a series of high-grade ...
To retrospectively evaluate the HER2 status of 1 501 invasive breast cancer (IBC) by immunohistochem...
Objective: The aim of this study was to determine the rate of Her-2 gene amplification in breast can...
INTRODUCTION: Overexpression of the human epidermal growth factor receptor 2 (HER2) as a result of H...
Breast cancer accounts for approximately one quarter of all cancers in females. HER2 gene amplificat...
Purpose: Human epidermal growth factor receptor–2 (HER2) status can be tested with immunohistochemis...
The tests that are currently available for the measurement of overexpression of the human epidermal ...
Variation in assay sensitivity was studied in more than 90 laboratories that assayed 4 formalin-fixe...
The HercepTest was approved 20+ years ago as the companion diagnostic test for trastuzumab in human ...